Biosimilar filgrastim (Zarzio) treatment patterns and relative dose intensity maintenance in patients receiving chemotherapy for the treatment of solid tumour or lymphoid malignancies

Trial Profile

Biosimilar filgrastim (Zarzio) treatment patterns and relative dose intensity maintenance in patients receiving chemotherapy for the treatment of solid tumour or lymphoid malignancies

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Acronyms ZOHe
  • Most Recent Events

    • 02 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Patients were recruited between June 2013 and April 2014, according results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top